Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q9BS18
UPID:
APC13_HUMAN
Alternative names:
Cyclosome subunit 13
Alternative UPACC:
Q9BS18; Q9Y3V0
Background:
Anaphase-promoting complex subunit 13, also known as Cyclosome subunit 13, plays a pivotal role in cell cycle regulation. It is a component of the anaphase promoting complex/cyclosome (APC/C), a cell cycle-regulated E3 ubiquitin ligase. This complex is crucial for controlling progression through mitosis and the G1 phase of the cell cycle by mediating ubiquitination and subsequent degradation of target proteins. It primarily facilitates the formation of 'Lys-11'-linked polyubiquitin chains, with lesser activity towards 'Lys-48'- and 'Lys-63'-linked chains.
Therapeutic significance:
Understanding the role of Anaphase-promoting complex subunit 13 could open doors to potential therapeutic strategies.